CN102015682B - 作为肾素抑制剂的3,4-取代的哌啶衍生物 - Google Patents

作为肾素抑制剂的3,4-取代的哌啶衍生物 Download PDF

Info

Publication number
CN102015682B
CN102015682B CN200980116219.5A CN200980116219A CN102015682B CN 102015682 B CN102015682 B CN 102015682B CN 200980116219 A CN200980116219 A CN 200980116219A CN 102015682 B CN102015682 B CN 102015682B
Authority
CN
China
Prior art keywords
methyl
equiv
amine
vacuo
etoac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980116219.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102015682A (zh
Inventor
A·C-Y·陈
D·迪布
P-A·富尼耶
E·L·格林
P·拉孔布
S·拉利贝特
D·麦唐纳
D·B·麦凯
D·J·麦凯
T·Y-H·吴
L-C·坎珀
J·P·斯科特
N·布勒迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Organon Pharma UK Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Merck Sharp and Dohme Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN102015682A publication Critical patent/CN102015682A/zh
Application granted granted Critical
Publication of CN102015682B publication Critical patent/CN102015682B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN200980116219.5A 2008-05-05 2009-05-04 作为肾素抑制剂的3,4-取代的哌啶衍生物 Expired - Fee Related CN102015682B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12652908P 2008-05-05 2008-05-05
US61/126529 2008-05-05
US18830308P 2008-08-07 2008-08-07
US61/188303 2008-08-07
PCT/CA2009/000611 WO2009135299A1 (en) 2008-05-05 2009-05-04 3, 4 - substituted piperidine derivatives as renin inhibitors

Publications (2)

Publication Number Publication Date
CN102015682A CN102015682A (zh) 2011-04-13
CN102015682B true CN102015682B (zh) 2014-07-16

Family

ID=41264366

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980116219.5A Expired - Fee Related CN102015682B (zh) 2008-05-05 2009-05-04 作为肾素抑制剂的3,4-取代的哌啶衍生物

Country Status (23)

Country Link
US (1) US8889714B2 (enExample)
EP (1) EP2274295B1 (enExample)
JP (3) JP4790871B2 (enExample)
KR (2) KR101403311B1 (enExample)
CN (1) CN102015682B (enExample)
AU (1) AU2009243875B2 (enExample)
BR (1) BRPI0912388A2 (enExample)
CA (1) CA2722734C (enExample)
CO (1) CO6311081A2 (enExample)
CR (1) CR11809A (enExample)
DO (1) DOP2010000329A (enExample)
EA (1) EA020853B1 (enExample)
ES (1) ES2548134T3 (enExample)
IL (1) IL208467A (enExample)
MA (1) MA32296B1 (enExample)
MX (1) MX2010012067A (enExample)
MY (1) MY152042A (enExample)
NI (1) NI201000188A (enExample)
NZ (1) NZ589019A (enExample)
PL (1) PL2274295T3 (enExample)
SG (1) SG192543A1 (enExample)
SV (1) SV2010003723A (enExample)
WO (1) WO2009135299A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20110237622A1 (en) * 2008-12-10 2011-09-29 Merck Frosst Canada Ltd. Renin inhibitors
TWI562977B (en) * 2010-11-05 2016-12-21 Bayer Ip Gmbh Process for the preparation of substituted n-(benzyl)cyclopropanamines by imine hydrogenation
UA112897C2 (uk) * 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CN107602381B (zh) * 2017-09-11 2021-03-16 陕西莱特光电材料股份有限公司 一种萘甲酸酯类衍生物及其制备方法
CN108033876A (zh) * 2017-12-20 2018-05-15 江汉大学 一种5-溴-2-氯苯甲醛的制备方法
EP3887357A1 (en) 2018-11-28 2021-10-06 Basf Se Pesticidal compounds
EP4143167B1 (en) 2020-04-28 2024-05-15 Basf Se Pesticidal compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128659A2 (en) * 2005-05-31 2006-12-07 Novartis Ag Piperazine derivative renin inhibitors.
CN101014594A (zh) * 2004-07-09 2007-08-08 斯皮德尔实验股份公司 哌啶衍生物作为肾素抑制剂
CN101094848A (zh) * 2004-12-30 2007-12-26 诺瓦提斯公司 有机化合物
CN101103002A (zh) * 2005-01-14 2008-01-09 诺瓦提斯公司 3,4(,5)-取代的四氢吡啶
CN101133025A (zh) * 2005-03-09 2008-02-27 诺瓦提斯公司 有机化合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
TR199800409T1 (xx) 1995-09-07 1998-05-21 F.Hoffmann-La Roche Ag Kalp ve b�brek yetersizli�inin tedavii�in yeni 4-(oksialkoksifenil)-3-oksi-piperidinler
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
JP2001504457A (ja) 1996-11-01 2001-04-03 ニトロメド インコーポレーテッド ニトロソ化およびニトロシル化ホスホジエステラーゼ阻害剤化合物、組成物及びその使用法
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
WO2003093267A1 (en) 2002-04-29 2003-11-13 Actelion Pharmaceuticals Ltd 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
BR0312000A (pt) 2002-06-27 2005-03-22 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
CN1780836A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为血管紧张肽原酶抑制剂的新型二氮杂双环壬烯和四氢吡啶衍生物
KR20060007041A (ko) 2003-04-29 2006-01-23 액테리온 파마슈티칼 리미티드 신규의 3,4-이치환된 1,2,3,6-테트라하이드로피리딘 유도체
CN1780833A (zh) 2003-04-30 2006-05-31 埃科特莱茵药品有限公司 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
CA2521938A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo[3.3.1]non-6-ene derivatives with a heteroatom at the 3-position as renin inhibitors
JP2006524654A (ja) 2003-04-30 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規アザビシクロノネン誘導体
KR20060015573A (ko) 2003-05-02 2006-02-17 액테리온 파마슈티칼 리미티드 신규한 디아자비시클로노넨 유도체
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
JP2007508262A (ja) 2003-10-13 2007-04-05 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネン誘導体およびその使用
WO2005040173A1 (en) 2003-10-23 2005-05-06 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
WO2005054243A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Diazabicyclononene derivatives and their use as renin inhibitors
AU2004295092A1 (en) 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2006021401A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicylononene derivatives
JP2008510755A (ja) 2004-08-25 2008-04-10 アクテリオン ファーマシューティカルズ リミテッド ビシクロノネン誘導体
WO2006021403A1 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Bicyclononene derivatives
WO2006021399A2 (en) 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives as renin inhibitors
WO2006058546A1 (en) 2004-12-01 2006-06-08 Actelion Pharmaceuticals Ltd Novel lactame derivatives as renin inhibitors
TW200634014A (en) 2004-12-08 2006-10-01 Actelion Pharmaceuticals Ltd Novel diazabicyclononene derivative
WO2006063610A1 (en) 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Heteroaryl substituted diazabicyclononene derivatives
RU2007132438A (ru) 2005-01-28 2009-03-10 Актелион Фармасьютикалз Лтд (Ch) Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии
WO2006092268A1 (en) 2005-03-02 2006-09-08 Actelion Pharmaceuticals Ltd Bicyclic five-membered heteroaryl derivatives and their use as renin inhibitors
AR055756A1 (es) 2005-03-31 2007-09-05 Speedel Experimenta Ag Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos
WO2006103275A1 (en) 2005-03-31 2006-10-05 Speedel Experimenta Ag 3,4,5-substituted piperidines as renin inhibitors
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
JP4297972B2 (ja) 2005-05-27 2009-07-15 アクテリオン ファーマシューティカルズ リミテッド 新規なピペリジンカルボン酸アミド誘導体
WO2006131884A2 (en) 2005-06-07 2006-12-14 Actelion Pharmaceuticals Ltd Thiazole substituted diazabicyclononane or-nonene derivatives as renin inhibitors
WO2007009250A1 (en) 2005-07-22 2007-01-25 Merck Frosst Canada Ltd. Renin inhibitors
WO2007034406A1 (en) 2005-09-22 2007-03-29 Actelion Pharmaceuticals Ltd Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin
WO2007034445A2 (en) 2005-09-26 2007-03-29 Actelion Pharmaceuticals Ltd Novel piperazine derivatives as renin inhibitors for cardiovascular events and renal insufficiency
WO2007049224A1 (en) 2005-10-25 2007-05-03 Actelion Pharmaceuticals Ltd Novel hexahydro- or octahydro-cyclopenta[c]pyrrole derivatives
EP1968940B1 (en) 2005-12-30 2014-04-02 Novartis AG 3 , 5-substitued piperidine compounds as renin inhibitors
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
AU2007210813A1 (en) * 2006-02-02 2007-08-09 Actelion Pharmaceuticals Ltd Secondary amines as renin inhibitors
EP2029542A2 (en) 2006-03-03 2009-03-04 Actelion Pharmaceuticals Ltd. Primary amines as renin inhibitors
AU2007224368A1 (en) 2006-03-08 2007-09-13 Actelion Pharmaceuticals Ltd New amines
ATE520690T1 (de) 2006-09-18 2011-09-15 Vitae Pharmaceuticals Inc Piperidinderivate als renin-inhibitoren
DE602007007664D1 (de) * 2006-11-17 2010-08-19 Merck Frosst Canada Inc Renininhibitoren
CA2688057A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
JP2010535716A (ja) 2007-08-07 2010-11-25 メルク フロスト カナダ リミテツド レニン阻害剤
US20100249163A1 (en) * 2007-12-04 2010-09-30 Daniel Dube Renin inhibitors
US20110152316A1 (en) 2008-05-22 2011-06-23 Austin Chih-Yu Chen 3,4-substituted piperidine derivatives as renin inhibitors
US20120190701A1 (en) 2009-08-18 2012-07-26 Merck Sharp & Dohme Corp. Renin inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101014594A (zh) * 2004-07-09 2007-08-08 斯皮德尔实验股份公司 哌啶衍生物作为肾素抑制剂
CN101094848A (zh) * 2004-12-30 2007-12-26 诺瓦提斯公司 有机化合物
CN101103002A (zh) * 2005-01-14 2008-01-09 诺瓦提斯公司 3,4(,5)-取代的四氢吡啶
CN101133025A (zh) * 2005-03-09 2008-02-27 诺瓦提斯公司 有机化合物
WO2006128659A2 (en) * 2005-05-31 2006-12-07 Novartis Ag Piperazine derivative renin inhibitors.

Also Published As

Publication number Publication date
JP5653842B2 (ja) 2015-01-14
KR20100131007A (ko) 2010-12-14
SV2010003723A (es) 2011-01-24
MA32296B1 (fr) 2011-05-02
JP2011225579A (ja) 2011-11-10
IL208467A0 (en) 2010-12-30
AU2009243875A1 (en) 2009-11-12
EP2274295A4 (en) 2012-03-28
CN102015682A (zh) 2011-04-13
MX2010012067A (es) 2010-12-06
BRPI0912388A2 (pt) 2017-09-26
NZ589019A (en) 2012-10-26
US20110053940A1 (en) 2011-03-03
EP2274295A1 (en) 2011-01-19
ES2548134T3 (es) 2015-10-14
CO6311081A2 (es) 2011-08-22
JP4790871B2 (ja) 2011-10-12
WO2009135299A1 (en) 2009-11-12
IL208467A (en) 2014-07-31
MY152042A (en) 2014-08-15
SG192543A1 (en) 2013-08-30
EP2274295B1 (en) 2015-08-05
DOP2010000329A (es) 2011-01-15
JP2011225580A (ja) 2011-11-10
PL2274295T3 (pl) 2016-01-29
KR101403311B1 (ko) 2014-06-05
EA201071269A1 (ru) 2011-06-30
EA020853B1 (ru) 2015-02-27
NI201000188A (es) 2012-02-02
JP5587246B2 (ja) 2014-09-10
CR11809A (es) 2011-01-10
US8889714B2 (en) 2014-11-18
CA2722734C (en) 2013-11-05
CA2722734A1 (en) 2009-11-12
JP2011519871A (ja) 2011-07-14
KR20130029116A (ko) 2013-03-21
AU2009243875B2 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
CN102015682B (zh) 作为肾素抑制剂的3,4-取代的哌啶衍生物
AU2009247262B2 (en) Amide compound
KR101214665B1 (ko) 트리아졸 유도체 또는 그의 염
CN104822680B (zh) 咪唑并吡啶化合物
TWI491595B (zh) 作為香草類化合物受體之配體之經取代苯基尿素及苯基醯胺
TWI353834B (en) Aryl- and heteroarylpiperidinecarboxylate derivati
JP2011520924A (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
CN1434806A (zh) 取代的咪唑神经肽yy5受体拮抗剂
JPWO2012036278A1 (ja) グリシントランスポーター阻害物質
JP2012511514A (ja) レニン阻害剤としての３，４−置換ピペリジン誘導体
TWI472524B (zh) 腎素抑制劑
JP2025518047A (ja) ＴＲＰＭ３媒介性障害を治療するためのピラゾロ［１，５－ａ］ピリジン誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Quebec

Applicant after: Merck Canada Inc.

Applicant after: Merck Sharp & Dohme

Address before: Quebec

Applicant before: Merck Frosst Canada Ltd.

Applicant before: Merck Sharp & Dohme

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: MERCK FROSST CANADA LTD. TO: MERCK (CANADA) CO., LTD.

ASS Succession or assignment of patent right

Owner name: ACTELION PHARMACEUTICALS LTD.

Free format text: FORMER OWNER: MERCK (CANADA) CO., LTD.

Effective date: 20131016

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20131016

Address after: Swiss Al Sewell

Applicant after: Actelion Pharmaceuticals Ltd.

Applicant after: Merck Sharp & Dohme

Address before: Quebec

Applicant before: Merck Canada Inc.

Applicant before: Merck Sharp & Dohme

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140716

Termination date: 20190504

CF01 Termination of patent right due to non-payment of annual fee